



October 21, 2021

SHORTAGE RESOLUTION

Subject: Celontin® (Methsuximide, USP) 300 mg Capsules – Supply Shortage Resolved

Dear Health Care Provider:

The purpose of this letter is to inform you that the supply disruption of Celontin® (Methsuximide, USP) 300 mg Capsules has been resolved. Celontin is available for order through the regular channels (i.e., pharmacy). The requirement to request Celontin directly through Pfizer for drop shipment has been removed.

Celontin is indicated for the control of absence (petit mal) seizures that are refractory to other drugs. Please refer to the full prescribing information and medication guide for further information available at <http://labeling.pfizer.com/ShowLabeling.aspx?id=555>.

Reporting Adverse Events

Healthcare providers are encouraged to report adverse events, including product defects, by contacting Pfizer at 1-800-438-1985 or by contacting the FDA at <http://www.fda.gov/Safety/MedWatch> or by calling 1-800-FDA-1088.

For additional medical questions related to Celontin, please contact Pfizer Medical Information at 1-800-438-1985.

Sincerely,

A handwritten signature in blue ink that reads 'Sveta Ferri'.

Sveta Ferri, PharmD
US Medical Affairs
Pfizer Inc.

(c) 2021 Pfizer Inc. All rights reserved.